Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000919574-25-004735
Filing Date
2025-08-13
Accepted
2025-08-13 20:47:56
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 9847
2 d11955420_ex99-a.htm EX-99 5087
3 d11955420_ex99-b.htm EX-99 806
  Complete submission text file 0000919574-25-004735.txt   17524
Mailing Address 111 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 111 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 650-392-8412
SUTRO BIOPHARMA, INC. (Subject) CIK: 0001382101 (see all company filings)

EIN.: 452441988 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-90656 | Film No.: 251213797
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 540 MADISON AVENUE 7TH FLOOR NEW YORK NY 10022
Business Address 540 MADISON AVENUE 7TH FLOOR NEW YORK NY 10022 2127025204
SUVRETTA CAPITAL MANAGEMENT, LLC (Filed by) CIK: 0001569064 (see all company filings)

EIN.: 453704500 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A